– USA, MA – Walden Biosciences, Inc., a private, venture-backed biotechnology company advancing disease-modifying therapies to transform the treatment of kidney disease, announced the appointment of Dr. Howard Mayer (M.D.) to its Board of Directors.
About Dr. Howard Mayer
Most recently, Dr. Mayer served as EVP, Head of Research and Development at Ipsen. Before his time at Ipsen, he was CMO at Shire, responsible for the hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience, and ophthalmology therapeutic areas. Before Shire, Dr. Mayer served as CMO at EMD Serono, a division of Merck KGaA. He has also held a variety of global roles including Head of Clinical Development and Medical Affairs for Virology at Pfizer, and Director of Clinical Research at Bristol-Myers Squibb.
Dr. Mayer earned his B.A. from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine. He completed his internship and residency at Mount Sinai Hospital and his fellowship at Harvard Medical School.
Dr. Mayer has been honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry in both 2011 and 2017.
About Walden Biosciences
Walden Biosciences is a private, venture-backed Phase 2 clinical development-stage company focused on developing breakthrough, disease-modifying medicines to treat kidney diseases. Walden is applying novel, multi-disciplinary approaches that directly target the kidney to prevent damage, slow disease progression, and restore kidney function. Walden’s programs address novel targets for therapeutic intervention, directly targeting two cell types critical for kidney function: podocytes and proximal tubular cells. Dysfunction of these cells is critical to hallmahall market majority of kidney diseases. Walden’s clinical-stage program is a humanized monoclonal antibody that inhibits suPAR, a cause of podocyte dysfunction and kidney disease, which is being evaluated in a Phase 2 Basket study. Walden’s second most advanced program, a small molecule that is designed to stabilize and restore the function of dynamin, an enzyme responsible for the maintenance of the cytoskeletal architecture and function of podocytes and proximal tubule cells will begin a clinical study in 2025. All of Walden’s programs offer the promise to deliver disease-modifying, breakthrough therapies that are readily combinable with the standard of care to transform the treatment of kidney disease.
For more information https://www.waldenbiosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.